Cannabinoids

InMed Pharmaceuticals to Report Third Quarter Fiscal 2021 Financial Results

Retrieved on: 
Thursday, May 6, 2021
Communication, Forward-looking statement, Cannabinoids, Natural phenols, Cannabinol

b'Cautionary Note Regarding Forward-Looking Information:\nThis news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities laws.

Key Points: 
  • b'Cautionary Note Regarding Forward-Looking Information:\nThis news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities laws.
  • Forward-looking information is based on management\'s current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements.
  • Forward-looking information in this news release includes statements about: delivering new therapeutic alternatives to patients that may benefit from cannabinoid-based medicines; developing a pipeline of cannabinoid-based medications, initially focused on the therapeutic benefits of cannabinol; leading the way in the clinical development of cannabinol; and reporting financial results on May 13, 2021.\nAll forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.\nNEITHER THE TORONTO STOCK EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.\n'

Hemp CBD Oil: Technological Advancements Offer Consumers More Choice Through the Continued Refinement and Extraction of THC Variants

Retrieved on: 
Tuesday, May 4, 2021
Drugs, Euphoriants, Appetite stimulants, Entheogens, Psychoactive drugs, Chemical compounds, Cannabinoids, Anticonvulsants, Cannabidiol, Hemp, Cannabis, Tetrahydrocannabinol

b'Las Vegas, May 04, 2021 (GLOBE NEWSWIRE) -- There\xe2\x80\x99s no denying that the CBD industry is booming.

Key Points: 
  • b'Las Vegas, May 04, 2021 (GLOBE NEWSWIRE) -- There\xe2\x80\x99s no denying that the CBD industry is booming.
  • This means consumers would either avoid them completely and buy CBD products, or experience them completely and buy THC products.\nNow, with great advancements in THC extraction, variations of hemp CBD oil , gummies, tinctures and more are being created that give consumers a choice of how much \xe2\x80\x98euphoria\xe2\x80\x99 they wish to experience:\nThe hemp industry is experiencing a real shift with the advancement of THC extraction.
  • CBD oil, gummies, distillate and more are now being rivalled by these alternatives that many consumers find more appealing.\nFresh Bros\xe2\x84\xa2 is much more than a licensed CBD and Hemp product manufacturer.
  • They focus on developing transparent, innovative, and reliable products and for high performance individuals, entrepreneurs, and consumers.

Green Hygienics Holdings Inc. (GRYN) Launches TruLife Biotech, LLC. to Advance the Study of Hemp-derived Cannabinoid Therapeutics

Retrieved on: 
Tuesday, May 4, 2021
Cannabinoids, Endocannabinoid system, Neurochemistry

b'SAN DIEGO, May 04, 2021 (GLOBE NEWSWIRE) -- via InvestorWire \xe2\x80\x93 Green Hygienics Holdings Inc. (OTCQB: GRYN) ("Green Hygienics" or the "Company"), announces today that it will move forward with the establishment of TruLife Biotech, LLC., to focus on the development and advancement of innovative cannabinoid-based nutraceuticals, skincare products and wellness brands addressing endocannabinoid system (ECS) deficiencies in humans.\n\xe2\x80\x9cThe interaction of hemp-derived cannabinoids with ECS has been rigorously studied for the last 20 years.

Key Points: 
  • b'SAN DIEGO, May 04, 2021 (GLOBE NEWSWIRE) -- via InvestorWire \xe2\x80\x93 Green Hygienics Holdings Inc. (OTCQB: GRYN) ("Green Hygienics" or the "Company"), announces today that it will move forward with the establishment of TruLife Biotech, LLC., to focus on the development and advancement of innovative cannabinoid-based nutraceuticals, skincare products and wellness brands addressing endocannabinoid system (ECS) deficiencies in humans.\n\xe2\x80\x9cThe interaction of hemp-derived cannabinoids with ECS has been rigorously studied for the last 20 years.
  • There\xe2\x80\x99s an awful lot of preclinical data available, and the question is how much is genuine, and practically useful, as far as efficacious, new nutraceutical and wellness product development is concerned.
  • \xe2\x80\x9cThe company will serve as a biotechnology innovations hub for the GRYN portfolio companies, and ultimately the Company will secure a strategic advantage in the marketplace by introducing novel cannabinoids and targeted bio-delivery technologies to the formulations within its own brand portfolio.\xe2\x80\x9d\nDr.
  • Darjania is a seasoned pharma-professional with over 20 years of experience in biotechnology and pharmaceutical drug research and development.

Remedy+ Does More Than Merely Take the Edge Off

Retrieved on: 
Tuesday, May 4, 2021
Pain, Drugs, Anticonvulsants, Organ systems, Analgesics, Cannabidiol, Cannabinoids, Resorcinols, CBD, Chronic pain

b'FORT LAUDERDALE, Fla., May 4, 2021 /PRNewswire/ --Remedy+ is striving to revolutionize the concept of CBD products.

Key Points: 
  • b'FORT LAUDERDALE, Fla., May 4, 2021 /PRNewswire/ --Remedy+ is striving to revolutionize the concept of CBD products.
  • They are marketed to audiences that are managing chronic pain, coping with stress, and otherwise looking for a way to take the edge off of life\'s challenges.
  • And while that may be one use for cannabidiol products, the folks at Remedy+ pose the question "why stop there?
  • In the words of the brand, its premium CBD products are "designed to help you perform better at work or play."

Delta 8 THC: Fresh Bros Explores the Reasons Why Delta 8 Products are Gaining in Popularity

Retrieved on: 
Monday, May 3, 2021
Drugs, Entheogens, Euphoriants, Appetite stimulants, Psychoactive drugs, Antiemetics, Cannabinoids, Branches of biology, Tetrahydrocannabinol, Hemp, Cannabis, Cannabidiol

Delta 8 is legal to buy online, so you can have complete peace of mind as long as you buy your products from a reputable supplier (after all, not all Delta 8 THC products are high quality!

Key Points: 
  • Delta 8 is legal to buy online, so you can have complete peace of mind as long as you buy your products from a reputable supplier (after all, not all Delta 8 THC products are high quality!
  • ).\nFresh Bros is a fully licensed and regulated CBD and hemp product manufacturer based in Las Vegas.
  • This is where Delta 8 truly shines, as these patients could take it to experience relief from pain and nausea without having to cope with any serious side effects.
  • In addition to providing relief from pain and nausea, Delta 8 offers some other great benefits to users, such as:\n'

cbdMD, Inc. to Host Conference Call to Discuss March 31, 2021, Second Quarter Results

Retrieved on: 
Monday, May 3, 2021
Retail, Alternative medicine, Specialty, Health, Drugs, Cannabinoids, Resorcinols, Analgesics, Anticonvulsants, Cannabidiol, CBD, Tetrahydrocannabinol

b'cbdMD, Inc. is one of the leading and most highly trusted and most recognized cannabidiol (CBD) brands with a comprehensive line of U.S. produced, THC-free1 CBD products.

Key Points: 
  • b'cbdMD, Inc. is one of the leading and most highly trusted and most recognized cannabidiol (CBD) brands with a comprehensive line of U.S. produced, THC-free1 CBD products.
  • Our cbdMD brand currently includes over 130 SKU\xe2\x80\x99s of high-grade, premium CBD products including CBD tinctures, CBD gummies, CBD topicals, CBD capsules, CBD bath bombs, CBD bath salts, CBD sleep aids and CBD drink mixes.
  • Please visit www.cbdMD.com , follow cbdMD on Instagram and Facebook , or visit one of the 6,000 retail outlets that carry cbdMD products.
  • cbdMD, Inc. does not undertake any duty to update any forward-looking statements except as may be required by law.

Dosecann Launches Industry-Leading, High-Potency Topical: Dosecann Daily Relief CBD Cream

Retrieved on: 
Monday, May 3, 2021
Drugs, Cannabinoids, Entheogens, Euphoriants, Anticonvulsants, Cannabidiol, Resorcinols, Cannabis, CBD, Organ systems, XC2

With 1,200mg of cannabidiol (CBD) per 60 ml unit, Dosecann Daily Relief CBD Cream has double the potency of any CBD topical currently available in the Canadian marketplace and is competitively priced to deliver the best value for a CBD topicali.

Key Points: 
  • With 1,200mg of cannabidiol (CBD) per 60 ml unit, Dosecann Daily Relief CBD Cream has double the potency of any CBD topical currently available in the Canadian marketplace and is competitively priced to deliver the best value for a CBD topicali.
  • \xe2\x80\x9cConsumers use topicals to provide daily relief from a wide variety of symptoms such as localized pain relief, muscle soreness, tension and inflammation.
  • Our team was driven to ensure that Dosecann Daily Relief CBD Cream offers industry-leading potency along with a formulation designed to boost CBD penetration and provide the skin moisturizing properties of high-end skin creams.\xe2\x80\x9d\n\xe2\x80\x9cWe\xe2\x80\x99re excited to launch Dosecann Daily Relief CBD Cream and expand our expertise in the 2.0 segment into topicals,\xe2\x80\x9d said Brad Canario, Brand Director, Auxly.
  • Dosecann Daily Relief CBD Cream\xc2\xa0has a mild, neutral bamboo scent and is packaged in a recyclable glass jar\xc2\xa0with\xc2\xa0a built-in seal to preserve freshness.\nDosecann Daily Relief CBD Cream is the latest cannabis 2.0 release from Auxly, who achieved the #1 market-share position for Cannabis 2.0 products in 2020.

"Dangerous Delta-8?" Mass CBD Manufacturer High Purity Natural Products Warns Consumers And Manufacturers About Potential Undetected And Harmful Chemicals

Retrieved on: 
Monday, May 3, 2021
Euphoriants, Entheogens, Appetite stimulants, Psychoactive drugs, Drugs, Medicinal plants, Cannabinoids, Branches of biology, Cannabis, Hemp, Tetrahydrocannabinol

States Gair Lauicus, Chief Science Officer at High Purity Natural Products.

Key Points: 
  • States Gair Lauicus, Chief Science Officer at High Purity Natural Products.
  • "\nMike Matton, President of High Purity: "Being well versed in cannabinoids and custom blended natural hemp-based products, we have been studying Delta-8 for a long time.
  • For this reason, High Purity Natural Products has decided not to engage in the manufacturing or sale of D8-THC products and hopes that any manufacturers will take proper precautions to provide safe products.
  • The company\'s innovative products provide opportunities across many retail, food, beverage, and supplement-based industries.\nView original content to download multimedia: http://www.prnewswire.com/news-releases/dangerous-delta-8-mass-cbd-manuf...\n'

Global CBD Nutraceuticals Market Report 2021-2028: Growing Shift Towards Health and Wellness Products has Significantly Increased the Demand

Retrieved on: 
Wednesday, April 28, 2021
Drugs, Health sciences, Health, Analgesics, Anticonvulsants, Cannabidiol, Cannabinoids, Resorcinols, Nutraceutical, Dietary supplement

The company launched several vegan products including supplements and food-grade products under its new line, MGC Nutraceuticals.

Key Points: 
  • The company launched several vegan products including supplements and food-grade products under its new line, MGC Nutraceuticals.
  • Its new offerings include capsules, water-soluble cannabinoids, and ready-to-drink products containing high-grade phytocannabinoids aimed at reducing stress, boosting immunity, and maintaining muscle and bone structure.
  • This product launch enables the company to tap growing opportunities in the dietary supplement and cannabidiol nutraceuticals market.\nOn the basis of product, the market is segmented into CBD capsules, CBD tinctures, and others.
  • The offline sales channel accounted for a major market share of the global CBD nutraceuticals industry.

InMed Pharmaceuticals Submits Clinical Trial Applications to Evaluate INM-755 (Cannabinol) Cream in a Phase 2 Trial for Epidermolysis Bullosa

Retrieved on: 
Wednesday, April 28, 2021
Genodermatoses, Rare diseases, Cannabinoids, Natural phenols, Epidermolysis bullosa, CBN, EB, Cannabinol, INM, Branches of biology

We are optimistic, based on our preclinical studies, that INM-755 cream may provide some much-needed help for these patients,\xe2\x80\x9d stated Alexandra Mancini, Senior Vice President of Clinical and Regulatory Affairs at InMed.

Key Points: 
  • We are optimistic, based on our preclinical studies, that INM-755 cream may provide some much-needed help for these patients,\xe2\x80\x9d stated Alexandra Mancini, Senior Vice President of Clinical and Regulatory Affairs at InMed.
  • The Company is dedicated to delivering new therapeutic alternatives to patients that may benefit from cannabinoid-based pharmaceutical drugs.
  • For more information, visit www.inmedpharma.com .\nAbout INM-755: INM-755 is a cannabinol (CBN) cream intended as a topical therapy to treat epidermolysis bullosa (EB) and potentially other dermatological diseases.
  • The disease has no approved cure and most current treatments are directed towards symptomatic relief.\n'